http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110278941-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-0226 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N1-02 |
| filingDate | 2019-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110278941-B |
| titleOfInvention | Isolated heart protection solution containing natriuretic peptide |
| abstract | The invention discloses an isolated heart protection solution containing natriuretic peptide, which is a mixture of natriuretic peptide and HTK solution. The natriuretic peptide is one of atrial natriuretic peptide, brain natriuretic peptide, C-type natriuretic peptide and artificially synthesized blood vessel natriuretic peptide. The concentration of the atrial natriuretic peptide, the brain natriuretic peptide, the C-type natriuretic peptide and the synthetic vascular natriuretic peptide in HTK solution is 10 ‑8 mol/L～10 ‑6 mol/L. The pH value of the in vitro heart protection solution is 7.2-7.4. The natriuretic peptide-containing isolated heart protection solution can effectively maintain isolated heart activity, improve cardiac function and inhibit myocardial inflammatory reaction. |
| priorityDate | 2019-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 173.